Literature DB >> 19629067

Pituitary gland: Medical therapy for acromegaly: can we predict response?

Andrea Giustina, Teresa Porcelli.   

Abstract

Response to medical therapy for acromegaly is highly variable, with few predictive factors available to help clinicians make informed treatment choices. Researchers in the UK now suggest that prior radiotherapy might influence an individual's response to secondary therapy with dopamine agonists or somatostatin analogs.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19629067     DOI： 10.1038/nrendo.2009.146

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


  10 in total

Review 1.  Criteria for cure of acromegaly: a consensus statement.

Authors:  A Giustina; A Barkan; F F Casanueva; F Cavagnini; L Frohman; K Ho; J Veldhuis; J Wass; K Von Werder; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  2000-02       Impact factor: 5.958

Review 2.  Treatment of acromegaly with dopamine agonists.

Authors:  C A Jaffe; A L Barkan
Journal:  Endocrinol Metab Clin North Am       Date:  1992-09       Impact factor: 4.741

3.  Consensus statement: medical management of acromegaly.

Authors:  S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal:  Eur J Endocrinol       Date:  2005-12       Impact factor: 6.664

4.  Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

Authors:  Pamela U Freda; Laurence Katznelson; Aart Jan van der Lely; Carlos M Reyes; Shouhao Zhao; Daniel Rabinowitz
Journal:  J Clin Endocrinol Metab       Date:  2005-05-10       Impact factor: 5.958

5.  Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.

Authors:  Annamaria Colao; Roberto Attanasio; Rosario Pivonello; Paolo Cappabianca; Luigi M Cavallo; Giovanni Lasio; Alessandro Lodrini; Gaetano Lombardi; Renato Cozzi
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

Review 6.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

7.  Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.

Authors:  A Fusco; M C Zatelli; A Bianchi; V Cimino; L Tilaro; F Veltri; F Angelini; L Lauriola; V Vellone; F Doglietto; M R Ambrosio; G Maira; A Giustina; E C degli Uberti; A Pontecorvi; L De Marinis
Journal:  J Clin Endocrinol Metab       Date:  2008-05-06       Impact factor: 5.958

Review 8.  Resistance to somatostatin analogs in acromegaly: an evolving concept?

Authors:  M Gola; S Bonadonna; G Mazziotti; G Amato; A Giustina
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

9.  Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.

Authors:  M Sherlock; E Fernandez-Rodriguez; A Aragon Alonso; R C Reulen; J Ayuk; R N Clayton; G Holder; M C Sheppard; A Bates; P M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2009-01-21       Impact factor: 5.958

10.  Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.

Authors:  Antonio Bianchi; Andrea Giustina; Vincenzo Cimino; Roberto Pola; Flavia Angelini; Alfredo Pontecorvi; Laura De Marinis
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958
  10 in total
  3 in total

Review 1.  Clinical implications of growth hormone-secreting tumor subtypes.

Authors:  Katja Kiseljak-Vassiliades; Shibana Shafi; Janice M Kerr; Tzu L Phang; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Endocrine       Date:  2012-03-21       Impact factor: 3.633

2.  STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion.

Authors:  Cuiqi Zhou; Yonghui Jiao; Renzhi Wang; Song-Guang Ren; Kolja Wawrowsky; Shlomo Melmed
Journal:  J Clin Invest       Date:  2015-03-16       Impact factor: 14.808

3.  A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis.

Authors:  Emmanuel Somm; Nicolas Bonnet; Alberto Martinez; Philip M H Marks; Verity A Cadd; Mark Elliott; Audrey Toulotte; Serge L Ferrari; René Rizzoli; Petra S Hüppi; Elaine Harper; Shlomo Melmed; Richard Jones; Michel L Aubert
Journal:  J Clin Invest       Date:  2012-08-01       Impact factor: 14.808
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.